CHRS
Coherus Oncology
$1.01
$0.00 (0%)Oct 26, 2026
Key metrics
The numbers that frame CHRS today
- Market cap
- $156.05M
- Gross margin
- 68.9%
- EV / Sales
- 2.2
- ROIC
- -562%
- Div yield
- 0%
- Debt / equity
- 0.6
- 52wk Low
- $0.94
- 52wk High
- $2.62
Growth
Revenue and earnings trend for CHRS
RevenueNet income
See the full growth breakdown
Revenue and earnings trends, margins and the multi-year trajectory - free with an account.
Create a free accountFree foreverNo card required
Already a member? Log inCash flow & returns
Free cash flow and financial health
Free cash flowNet debt
See the full cash-flow picture
Free cash flow detail, returns on capital and the balance-sheet trend - free with an account.
Create a free accountFree foreverNo card required
Already a member? Log inInsider trading
Recent insider buying and selling activity
PurchasesSales
Unlock every insider trade
See who is buying and selling, how much, and when - updated as new filings land.
Create a free accountFree foreverNo card required
Already a member? Log inFrequently asked questions
Plain-English answers about CHRS
Is Coherus Oncology a good buy?
No. Coherus Oncology has poor quality and poor momentum. Both signals point to a weaker setup. Growth looks weak. That could put pressure on the long-term business case. We think Coherus Oncology is selling at a very high price.
What is the market capitalization of CHRS?
Coherus Oncology's market capitalization is $156.05M.
What is the 52-week high for CHRS stock?
The 52-week high for Coherus Oncology is $2.62. The current close of $1.01 is 61.4% below that high.
What is the 52-week low for CHRS stock?
The 52-week low for Coherus Oncology is $0.94. The current close of $1.01 is 7.4% above that low.
Does CHRS stock pay dividends?
Coherus Oncology does not currently show a dividend per share in the company data.
What is the Debt / Equity ratio for CHRS?
Coherus Oncology's Debt / Equity ratio is 0.61.